Showing results (111-120 of 1,348) with videos related to

Sort By:
Pageof 135
Clinical Pharmacology in Drug Development|January 17, 2019
A Phase 1 Randomized, Placebo-Controlled Trial With a Topical Inhibitor of Stearoyl-Coenzyme A Desaturase 1 Under Occluded and Nonoccluded ConditionsRichard A Brigandi, John Zhu, Amy A Murnane, et al.
Clinical Pharmacology in Drug Development|December 11, 2019
Preemptive Anti-Stress Response Effects of Oxycodone Versus Sufentanil for Patients Undergoing Cardiac Valve Replacement-A Randomized Controlled TrialJian Zhang, Qing Tu, Jianhui Gan, et al.
Clinical Pharmacology in Drug Development|December 12, 2019
Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese SubjectsMeng Wang, Wenjia Zhou, Quanying Zhang, et al.
Clinical Pharmacology in Drug Development|February 21, 2018
Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG-CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in JapanMasayuki Hashiguchi, Junya Maruyama, Mikiko Shimizu, et al.
Clinical Pharmacology in Drug Development|July 2, 2016
Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or AripiprazoleBart Remmerie, Marc De Meulder, Sveta Weiner, et al.
Clinical Pharmacology in Drug Development|August 8, 2017
Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy WomenBing Zhu, Ivan Nestorov, Guolin Zhao, et al.
Clinical Pharmacology in Drug Development|August 8, 2017
Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic StudyYoshishige Samukawa, Michio Sata, Kenichi Furihata, et al.
Clinical Pharmacology in Drug Development|November 14, 2018
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy SubjectsJohn P Hanrahan, James D Wakefield, Phebe J Wilson, et al.
Clinical Pharmacology in Drug Development|March 25, 2017
Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 StudySusanne A Johansson, Mikael Knutsson, Maria Leonsson-Zachrisson, et al.
Clinical Pharmacology in Drug Development|November 22, 2016
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled StudyWilliam S Denney, Douglas S Denham, Michael R Riggs, et al.
Pageof 135